Document:

Exhibit

Exhibit 10.1

FIRST AMENDMENT
TO
EXECUTIVE EMPLOYMENT AGREEMENT

This First Amendment (the “First Amendment”) to that certain Executive Employment Agreement between Radius Health, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Robert Ward (the “Executive”) dated as of December 12, 2013 (the “Employment Agreement”) is made as of this 1st day of July, 2015 (the “Amendment Date”), by and among the Company and the Executive.  Except as set forth in this First Amendment, capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement.
WITNESSETH
WHEREAS, the Company and the Executive desire to amend the terms of the Employment Agreement as set forth herein.
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Executive and the Company hereby agree to the following:
1.Amendment to the Employment Agreement.  Effective as of the Amendment Date, Section 8(e) of the Employment Agreement is hereby amended and restated in its entirety to read as follows:
(e)    TERMINATION WITHOUT CAUSE OR FOR GOOD REASON FOLLOWING A CHANGE OF CONTROL.  If the Executive’s employment by the Company is terminated by the Company other than for Cause (and not due to Disability or death), or by the Executive for Good Reason, in either case on or within twenty-four (24) months immediately following a Change of Control (as defined in the Plan, disregarding for this purpose clause (d) of such definition), then the Company shall pay or provide the Executive with the Accrued Amounts and all of the benefits described in Section 8(d) above, subject to compliance with Section 11; provided that: (i) the Salary Severance Period defined in Section 8(d)(1) shall be increased to a total of eighteen (18) months following the termination date; (ii) the COBRA Severance Period defined in Section 8(d)(2) shall be increased to a total of eighteen (18) months following the termination date; (iii) in lieu of the pro-rata bonus described in Section 8(d)(4), the Company shall pay the Executive one-hundred fifty percent (150%) of the Target Bonus for the performance year in which the Executive’s termination occurs, payable as a lump sum payment on the Company’s first ordinary payroll date occurring on or after the General Release effective date (namely, the date it can no longer be revoked); and (iv) in lieu of the vesting acceleration described in Section 8(d)(5), all of the outstanding unvested shares subject to the Executive’s Company equity or equity-based awards shall become fully vested and the time period that the Executive may have to exercise such awards shall be extended for a period equal to the shorter of (i) nine (9) months, or (ii) the remaining term of the award.
2.Non-Compete Agreement.  As a condition to the effectiveness of this First Amendment, Executive will execute and deliver to the Company the Confidentiality and Non-Competition Agreement attached as Exhibit A.
3.No Other Amendment.  Except as expressly set forth in this First Amendment, the Employment Agreement shall remain unchanged and shall continue in full force and effect according to its terms.

4.Counterparts.  This First Amendment may be executed in several counterparts, each of which shall be deemed an original and all of which together shall constitute one document.
IN WITNESS WHEREOF, the parties have executed this First Amendment as of the Amendment Date.

RADIUS HEALTH, INC.

By:  /s/ Kurt C. Graves   July 9, 2015
Name:  Kurt C. Graves
Title:  Chairman of the Board of Directors

EXECUTIVE

/s/ Robert Ward    
Robert Ward

    

Exhibit A

Confidentiality and Non-Compete Agreement

[attached]

    

Confidentiality and Non-Competition Agreement
In consideration for the agreement of Radius Health, Inc., its subsidiaries, affiliates, successors or assigns (together the “Company”) to employ me as an employee or consultant and my receipt of the compensation now and hereafter paid to me by the Company, I agree as follows:
1.Definition of Confidential Information.  I acknowledge that I may be furnished or have access to confidential, proprietary or trade secret information relating to the Company’s past, present or future (a) products, processes, formulas, patterns, compositions, compounds, projects, specifications, know how, research data, clinical data, personnel data, compilations, programs, devices, methods, techniques, inventions, software code, developments, documentation, original works of authorship, designs and technical data, and improvements thereto (collectively, “Technology”); (b) research and development activities, (c) marketing, business or business development activities, including without limitation prospective or actual bids or proposals, pricing information and financial information; (d) customers or suppliers; or (e) other administrative, management, planning, financial, marketing, purchasing or manufacturing activities.  All of this type of information, whether it belongs to the Company or was provided to the Company by a third party with the understanding that it be kept confidential, and any documents, diskettes or other storage media, or other materials or items containing this type of information, are proprietary and confidential to the Company (“Confidential Information”).
2.Obligations.  I agree to preserve and protect the confidentiality of Confidential Information both during and after my employment with the Company.  In addition, I agree not to, at any time during the term of this Confidentiality and Non-Competition Agreement (this “Agreement”) or thereafter, (a) disclose or disseminate Confidential Information to any third party, including without limitation employees or consultants of the Company without a legitimate business need to know; (b) remove Confidential Information from the Company’s premises or make copies of Confidential Information, except as required to perform my job; or (c) use Confidential Information for my own benefit or for the benefit of any third party.  I also agree to take all actions necessary to avoid unauthorized disclosure and otherwise to maintain the confidential or proprietary nature of such Confidential Information.  If I am not certain whether or not information is confidential, I will treat that information as Confidential Information until I have verification from the Company’s Personnel Officer that the information is not Confidential Information.
3.Exceptions.  The Company agrees that the obligations in Section 2 do not apply to any information that I can establish (a) has become publicly known without a breach of this Agreement by me or a third party’s breach of an agreement to maintain the confidentiality of the information; or (b) was developed by me prior to the date this Agreement is signed, and prior to the date any earlier Confidentiality Agreement of the Company was signed, if the date of development can be established by documentary evidence.  For the purposes of clause (a) of the preceding sentence, Confidential Information will be deemed to have become publicly known 

    

only if I can establish that all material features comprising such information have become publicly known.
4.Former Employer Information.  I agree that I will not, during my employment with the Company, improperly use or disclose any proprietary information or trade secrets of any former or current employer or any other person or entity and that I will not bring onto the premises of the Company any unpublished document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity.
5.Inventions and Works Retained and Licensed.  I have attached hereto, as Exhibit A, a list describing all Technology which was created, made, conceived, developed or reduced to practice (collectively, “Developed”) by me, solely or jointly,  prior to my employment with the Company (collectively referred to as “Prior Works or Inventions”), which belong to me, which relate to the Company’s business, products, or research and development, and which are not assigned to the Company hereunder, or, if no such list is attached, I represent that there are no such Prior Works or Inventions.  If, in the course of my employment with the Company, I incorporate into a Company product, process or machine, or otherwise use for the benefit of the Company, a Prior Work or Invention, whether or not listed, owned by me or in which I have an interest, the Company is hereby granted and shall have a nonexclusive, royalty-free, assignable, irrevocable, perpetual, worldwide license to make, have made, modify, reproduce, distribute, prepare derivative works of, use, import, offer to sell, sell and otherwise exploit such Prior Work or Invention, including without limitation as part of or in connection with such product, process or machine or other use of the same.
6.Ownership of Work Product.  
(a)    I agree that the Company owns all right, title and interest in, including without limitation all trade secrets, patent rights, copyrights, trademarks, and other intellectual property rights (collectively, “Intellectual Property Rights”) in the following works that I Develop, solely or jointly, during and for one (1) year after termination of my employment with the Company:  (i) Technology that is created using the Company’s facilities, supplies, information, trade secrets or time, (ii) Technology that relates directly or indirectly to or arises out of the actual or proposed business of the Company, including, without limitation the research and development activities of the Company, (iii) Technology that relates directly or indirectly to or arises out of any task assigned to me or work I perform for the Company  or (iv) Technology that is based on Confidential Information (collectively “Work Product”).  Because any Work Product will inevitably be based upon or somehow involve the Company’s business, products, services or methodologies, I agree that any Work Product will belong to the Company even if I Develop it on my own time, using my own equipment, whether on the Company’s premises or elsewhere.  I will promptly provide full written disclosure to an officer of the Company of any Work Product I Develop, solely or jointly, during the term and for a period of one (1) year thereafter.  I hereby irrevocably assign and agree to assign to the Company the ownership of, and all Intellectual Property Rights in, the Work Product.  The Company will have the right to hold in its own name 

    

all rights in the Work Product, including without limitation all Intellectual Property Rights therein.  I also waive all claims to moral rights in any Work Product.
(b)    I agree to cooperate fully with the Company, both during and after my employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other Intellectual Property Rights (both in the United States and foreign countries) relating to Work Product.  I agree to execute and deliver all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable to protect its rights and interests in any Work Product.  I further agree that if the Company is unable, after reasonable effort, to secure my signature on any such papers, any executive officer of the Company shall be entitled to execute any such papers as my agent and attorney-in-fact, and I hereby irrevocably designate and appoint each executive officer of the Company as my agent and attorney-in-fact to execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable to protect its rights and interests in any Work Product, under the conditions described in this sentence.
7.Maintenance of Records.  I agree to keep and maintain adequate and current written records of all Work Product made by me (solely or jointly with others) during the term of my employment with the Company.  The records will be in the form of notes, sketches, drawings, and any other format that may be specified by the Company.  The records will be available to and remain the sole property of the Company at all times.
8.Return of Confidential Information.  I agree to return to the Company all Confidential Information in my possession, custody or control immediately upon my termination, or earlier, from the Company for any reason, if the Company requests.
9.Notification of New Employer.  In the event I leave the employ of the Company for any reason, I hereby grant consent to notification by the Company to my new employer about my rights and obligations under this Agreement.
10.Noncompetition; Nonsolicitation of Employees.  In order to protect the value of any Confidential Information, I agree to the following provisions against unfair competition, which I acknowledge represent a fair balance of the Company’s rights to protect its business and my right to pursue employment: 
(a)    While I am employed (whether as an employee or consultant) at the Company and for a period (the “Restricted Period”) immediately following termination of such employment (for any reason whatsoever, whether voluntary or involuntarily) of (i) one year or (ii) if later, until the end of the Salary Severance Period (as defined in the Employment Agreement, dated December 12, 2013, between me and the Company, as may be amended from time to time (the “Employment Agreement”), I agree that I will not, whether alone or as a partner, officer, director, consultant, agent, representative, employee or security holder of any company or their commercial enterprise, directly or indirectly engage in, have an equity interest in, interview for a potential employment or consulting relationship with or manage, provide services to or operate any person, firm, corporation, partnership, association, other entity or business or other activity 

    

anywhere in the world that engages in business that is competitive with or renders services to any firm or business organization which competes with the business of the Company, which business includes, without limitation, the research, discovery and/or development of therapeutics to treat osteoporosis or hot flashes, or any other therapeutics that the Company is actively engaged in at the time of termination of your employment (the “Company’s Business”); provided, that the Company’s Business shall not include any business that the Company has not taken more than de minimis steps to engage in at the time of your termination of employment.  The foregoing prohibition shall not prevent my employment or engagement after termination if such employment or engagement, in any capacity, does not involve work or matters related to the Company’s Business.  I shall be permitted to own securities of a public company not in excess of five (5%) of any class of such securities and to own stock partnership interests or other securities of any entity not in excess of five (5%) of any class of such securities and such ownership shall not be considered to be competition with the Company.
(b)    While I am employed (whether as an employee or consultant) at the Company and for the Restricted Period, I agree that I will not (i) directly or indirectly solicit, recruit or induce any employee, customer, subscriber, supplier, vendor or business affiliate of the Company to terminate its employment or other arrangement with the Company or otherwise alter its relationship with the Company or (ii) directly or indirectly, for myself or any other person or entity, solicit or recruit any employee of the Company to work for a third party other than the Company or hire any such employee during the employee’s employment with the Company and for a period of twelve months following the employee’s employment with the Company or engage in any activity that would cause or encourage any employee to violate any agreement with the Company.
(c)    In the event the terms of this Section 10 shall be determined by any court of competent jurisdiction to be unenforceable by reason of its extending for too great a period of time or over too great a geographical area or by reason of its being too extensive in any other respect, it will be interpreted to extend only over the maximum period of time for which it may be enforceable, over the maximum geographical area as to which it may be enforceable, or to the maximum extent in all other respects as to which it may be enforceable, all as determined by such court in such action.
11.Representations and Warranties.  I represent and warrant that (a) I am able to perform the duties of my position and that my ability to work for the Company is not limited or restricted by any agreements or understandings between me and other persons or companies; (b) I will not disclose to the Company, its employees, consultants, clients, teaming partners or suppliers, or induce any of them to use or disclose, any confidential information or material belonging to others, except with the written permission of the owner of the information or material; and (c) any information, material or product I create or develop for, or any advice I provide to, the Company, its employees, consultants, clients, teaming partners or suppliers, will not rely or be based on confidential information or trade secrets I obtained or derived from a source other than the Company.  I agree to indemnify and hold the Company harmless from damages, claims, costs and expenses based on or arising from the breach of any agreement or 

    

understanding between me and another person or company or from my use or disclosure of any confidential information or trade secrets I obtained from sources other than the Company.
12.Damages and Injunctive Relief.  I acknowledge and agree that:
(a)    My obligations under this Agreement have a unique and substantial value to the Company and I remain obligated even if I voluntarily or involuntarily leave the Company’s employment.  I understand that if I violate this Agreement during or after my employment, the Company may be able to recover monetary damages from me and/or the other relief described below.
(b)    I agree that a violation or even a threatened violation of this Agreement is likely to result in irreparable harm to the Company and its goodwill, the exact amount of which will be difficult or impossible to ascertain, and monetary damages alone will not completely compensate the Company for the harm.  Accordingly, the Company may obtain an injunction prohibiting me from violating this Agreement, an order requiring me to render specific performance of the Agreement, and/or any other remedy which may be available at law or in equity.
(c)    If a court determines that I have breached or attempted or threatened to breach this Agreement, I consent to the granting of an injunction restraining me from further breaches or attempted or threatened breaches of this Agreement, compelling me to comply with this Agreement, and/or prescribing other equitable remedies.
13.Miscellaneous Provisions.
(a)    No failure or delay to act by the Company will waive any right, remedy or power contained in this Agreement.  Any waiver by the Company must be in writing and signed by an officer of the Company to be effective.
(b)    The provisions of this Agreement are applicable to Confidential Information and Work Product disclosed, developed or proprietary before or after I sign this Agreement.
(c)    This Agreement is to be construed according to its fair meaning and not strictly for or against either party.
(d)     This Agreement will be governed by the law of the Commonwealth of Massachusetts without regard to its conflicts of laws provisions that would result in the application of the laws of any other jurisdiction.  Suit to enforce any provision of this Agreement or to obtain any remedy with respect hereto may be brought in a courts of the Commonwealth of Massachusetts and for this purpose I expressly consent to the jurisdiction of said courts.
(e)    If any provision of this Agreement conflicts with the law of the Commonwealth of Massachusetts or if any provision is held invalid by a court with jurisdiction over the parties to this Agreement, the provision will be deemed to be restated to reflect as nearly as possible the parties’ original intentions in accordance with applicable law, and the remainder of the Agreement will remain in full force and effect.  If it is not possible to restate the provision in a 

    

legal and valid manner, then the provision will be deemed not to be a part of the Agreement and the remaining provisions will remain in full force and effect.
(f)    This document constitutes the entire agreement between the Company and me concerning the matters addressed in this Agreement and with respect to all periods after the date hereof it supersedes any prior agreement concerning those matters.  This Agreement shall constitute the Confidentiality Agreement for purposes of the Employment Agreement.  This Agreement may not be changed in any respect except by a written agreement signed by both parties.  Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.
(g)    All remedies provided in this Agreement are cumulative and in addition to all other remedies which may be available at law or in equity.

	
		
	Signature:
	 

	

Print Name:
	

Robert Ward

	

Date:
	

	

THE COMPANY:
	

RADIUS HEALTH, INC.

	

By:
	

	

Title:
	

    

Exhibit A

None.EX4-1

METHANEX CORPORATION

STOCK OPTION PLAN 2017

(Amended and Restated to Reflect Amendments approved by the

Board of Directors to and including March 3, 2017; 

approved by shareholders on April 27, 2017)

A.                   THE PLAN

                  The Stock Option Plan 2017 (the "Plan") is the amended and restated stock option plan of Methanex Corporation ("Corporation"), reflecting amendments to and including March 3, 2017, of the prior Stock Option Plan in effect before that date.  The Plan for key employees and directors of the Corporation and its majority-owned subsidiaries ("subsidiaries") to purchase unissued common shares of the Corporation ("Shares") has been established on the terms and conditions hereinafter set out.

B.                   PURPOSE

                  The purpose of the Plan is to develop the interest of key employees of the Corporation and its subsidiaries in growth and development by providing them with the opportunity through options on Shares to acquire an increased financial interest in the Corporation.

C.                   GRANT OF OPTIONS

                  Prior to March 3, 2017, the Board of Directors of the Corporation has from time to time in its discretion granted to officers, directors and other employees of the Corporation and its subsidiaries options to acquire Shares.  The Board of Directors of the Corporation may from and after March 3, 2017, from time to time in its discretion grant to officers and other employees of the Corporation (who in each case must be regularly employed (on a full-time or part-time basis) by the Corporation or a subsidiary and who, in the opinion of the Board of Directors, are key employees), an option to acquire all or any part of an allotment of Shares upon and subject to such terms, conditions and limitations as are herein contained and otherwise as the Board of Directors may from time to time determine with respect to each option. For greater certainty, such terms may include, without limitation, provision for immediate forfeiture of outstanding options and/or payment of cash compensation to the Corporation and/or return of Shares to the Corporation where, as a result of any gross negligence, fraud or other illegal conduct of an officer or employee of the Corporation or a subsidiary: (i) the Corporation has to restate its financial results; or (ii) it later becomes clear that metrics used and which formed the basis of any employee incentive compensation were not in fact achieved. Effective March 2, 2007, the Board of Directors may not grant options to non-management directors under the Plan.  From and after January 28, 2010, at the discretion of the Board of Directors of the Corporation, an option granted under this Plan may have connected therewith at the time of grant, a number of stock appreciation rights ("SARs"), which number must be fixed on the date of the grant of the option to which such SARs are connected and upon and subject to such terms, conditions and limitations as are herein contained and otherwise as the Board of Directors may from time to time determine with respect to each SAR.

                  An optionee who has been granted SARs may exercise such SARs, subject to the satisfaction of any applicable vesting condition, by surrendering to the Corporation, unexercised, the right to subscribe for one Share pursuant to the related option.  Upon such exercise, the optionee or, where the optionee has died, the person who exercises the SAR pursuant to clause (a) of Section E., shall receive from the Corporation cash in an amount equal to the excess of the US Dollar closing price of a Share on the Nasdaq Global Market on the most recent day preceding the exercise date upon which Shares were traded on such Exchange over the Grant Price (defined below) under the related option determined in accordance with Section D. of the Plan (adjusted where applicable in accordance with Section H.), net of any applicable withholding taxes and other required source deductions. 

                  Each exercise of a SAR shall cancel that option in respect of such Share and such option shall be of no further force or effect.  An unexercised SAR in respect of a Share shall terminate when the related Option is exercised in respect of such Share, or if the Option is not so exercised, when such Option ceases to be exercisable under the Plan. Shares subject to any Option that expires, is forfeited or that is cancelled on exercise of a SAR will be credited to the Corporation's Share reserve and will be available for future Option grants under the Plan.

                  The maximum number of Shares that may be issued from and after April 27, 2017 pursuant to options granted pursuant to this Plan is 6,304,155.  The maximum number of Shares which may be reserved for issuance to, or covered by any option granted to, any single person shall not exceed the lower of 5% of the outstanding issue or the maximum number permitted by the applicable securities laws and regulations of Canada or of the United States or any political subdivision of either, and the by-laws, rules and regulations of any stock exchange or other trading facility upon which the Shares are listed or traded, as the case may be. 
           The maximum number of Shares:

(i)        issued to insiders of the Corporation pursuant to options under the Plan within any one year period, or 

(ii)       issuable to insiders of the Corporation pursuant to options under the Plan at any time, 

shall not, when combined with all of the Corporation's other security based compensation arrangements, exceed 10% of the Corporation's total issued and outstanding securities.

D.                   GRANT PRICE

                  The price of the Shares, upon exercise of each option granted under the Plan, shall be a price fixed for such option by the Board of Directors, but such price shall be not less than the fair market value of the Shares on the date the option is granted.  For the purposes of the Plan, the fair market value on the grant date shall be deemed to be the US Dollar equivalent of the closing price of a Share on the Toronto Stock Exchange on the most recent day preceding the grant date upon which Shares were traded on such Exchange ("Grant Price"). The "US Dollar equivalent of the closing price" shall be determined using the US Dollar/Canadian Dollar Daily Noon Rate as published by the Bank of Canada on the same day that the closing price is established.

E.                   TERM

                  The Shares identified in the option may be purchased, and any SAR connected with an option may be exercised at such time or times after the option is granted as may be determined by the Board of Directors and as is set forth in the option agreement between the optionee and the Corporation.

                  Each option, unless sooner terminated in accordance with the terms, conditions and limitations of the option, and any SAR connected therewith, shall expire on a date ("Expiry Date") not later than, with respect to options granted prior to 2005, ten years from the day the option was granted, and, with respect to options granted in 2005 or later, seven years from the day the option was granted, which date shall be fixed by the Board of Directors, except that, subject to the right of the Board of Directors, in its discretion, to determine that a particular option may be exercisable during different periods, in respect of a different amount or portion of shares or in a different manner: 
(a)        in the case of the death of an optionee prior to the Expiry Date, each option held by the optionee will vest immediately and will be exercisable by the legal representative of such optionee, or by the person or persons to whom the optionee's rights under the option pass by will or the laws of devolution or distribution and descent, prior to the earlier of (i) the date which is one year from the date of death of such optionee (or such shorter or longer period as may be determined by the Board of Directors at the time of grant of the option), and (ii) the Expiry Date;

(b)        if an optionee ceases to be an officer or employee of the Corporation or an officer or employee of a subsidiary of the Corporation prior to the Expiry Date as a result of the optionee being unable, by reason of physical or mental health, to perform the duties of the optionee's position, each option held by the optionee will vest immediately and will be exercisable until the Expiry Date;

(c)        if an optionee ceases to be an officer or employee of the Corporation or an officer or employee of a subsidiary of the Corporation prior to the Expiry Date as a result of (i) the termination of the optionee's employment as a result of an Eligible Retirement of the optionee, or (ii) the termination by the optionee's employer of the optionee's employment by reason of a major divestiture or disposition of assets, facility closure or major downsizing, each option held by the optionee shall continue to vest in accordance with the terms and conditions thereof and will be exercisable until the Expiry Date; and

(d)        if an optionee ceases to be an officer or employee of the Corporation or an officer or employee of a subsidiary of the Corporation prior to the Expiry Date in circumstances other than as described in clauses (a), (b) or (c) above, each option held by the optionee that vests prior to the earlier of (A) the date which is 90 days following the date such optionee so ceases to be an officer or employee of the Corporation or an officer or employee of any subsidiary of the Corporation, or such earlier or later date as the Board of Directors may, in its discretion, determine; and (B) the Expiry Date, will be exercisable by the optionee until the earlier of the dates determined under clauses (A) and (B).

                  Notwithstanding the foregoing provisions, if any option will, apart from this paragraph, expire or, pursuant to the foregoing provisions of this section E, cease to be exercisable during any Blackout Period or within the 10 business days immediately after the last day of a Blackout Period, the option will be exercisable until, and will expire on, the date which is 10 business days after the last day of the Blackout Period and such 10th business day shall be considered the expiration date for such option for all purposes under this Plan.

                  As used in the Plan, the following terms shall have the meanings indicated:
(a)        "Blackout Period" means any period during which a policy of the Corporation or any "affiliate" of the Corporation (within the meaning of that expression as used in the Securities Act (British Columbia)) prohibits or prevents any optionee from trading Shares or exercising an option;

(b)        "business day" means a day, other than Saturday, Sunday and any other day which is a statutory holiday in British Columbia or on which the Shares are not available for trading on the facilities of the Toronto Stock Exchange or through the Nasdaq Global Market; and

(c)        "Eligible Retirement" means an optionee's termination of employment with the Corporation or a subsidiary (other than in connection with a transfer of employment from the Corporation to a subsidiary or vice versa or a termination of the optionee's employment by the Corporation or a subsidiary for cause) in circumstances meeting each of the following conditions: (i) the optionee has been continuously employed by the Corporation and/or a subsidiary for a minimum of 5 years; (ii) the optionee has notified the Corporation or the subsidiary by which he or she is employed of his or her intended termination of employment at least 30 days prior thereto; and (iii) the optionee has attained 55 years of age.

                  A change in the duties or position of an optionee or the transfer of such optionee from a position with the Corporation to a position with a subsidiary of the Corporation, or vice versa, will not trigger the termination of such optionee's option, provided such optionee remains an officer or employee of the Corporation or an officer or employee of any subsidiary of the Corporation.

                  Shares subject to an option which is not exercised or which is cancelled shall become available for subsequent options under the Plan.

F.                   ISSUE OF SHARES

                  No person shall have any of the rights of a shareholder in respect of any Shares under an option until such shares have been paid for in full and issued to such person.

G.                   TRANSFERABILITY

                  No option shall be transferable or assignable otherwise than by will or the laws of succession and distribution.

H.                   ALTERATION OF NUMBER OF SHARES SUBJECT TO THE PLAN

                  The number of Shares subject to the Plan shall be increased or decreased proportionately in the event of the subdivision or consolidation of such Shares, and in any such event a corresponding adjustment shall be made changing the number of shares deliverable upon the exercise of any option theretofore granted without change in the total price applicable to the unexercised portion of the option, but with a corresponding adjustment in the price for each share covered by the option, and any SAR connected with such option shall be adjusted accordingly.  In the event that the Corporation is reorganized or merged or consolidated or amalgamated with another corporation, appropriate provisions shall be made for the continuance of the options and SARs outstanding under the Plan and to prevent a material dilution or enlargement of any optionee's rights with respect to any such options or SARs.

I.                   ADMINISTRATION

                  Within the limitations set forth in the Plan, the Board of Directors, or any Committee of the Board to which such authority shall be delegated by the Board, is authorized to provide for the grant and exercise of options on such terms (which may vary as between options) as it shall determine.  All decisions and interpretations made by the Board of Directors, or any such committee, shall be binding and conclusive on the Corporation and all employees eligible to participate in the Plan.

J.                     AMENDMENT AND TERMINATION

                  The Board of Directors may at any time terminate the Plan with respect to any Shares not at the time subject to option.  Subject to the following paragraph, the Board of Directors may at any time and from time to time amend, without shareholder approval, any of the provisions of the Plan or any option or SAR, subject to obtaining any required approval of any applicable stock exchange or other regulatory authority (provided that any such amendment may not, without the consent of the optionee, adversely affect or impair any option or SAR previously granted to an optionee under the Plan), in respect of the following:
(a)        to make any clerical or administrative changes (including a change to correct or rectify an ambiguity, immaterial inconsistency, defective provision, mistake, error or omission, or clarify the Plan's provisions or a change to the provisions relating to the administration of the Plan);

(b)        to change provisions relating to the manner of exercise of options or SARs, including changing or adding any form of financial assistance provided by the Corporation to participants or, if the Plan has a fixed maximum number of securities issuable, adding provisions relating to a cashless exercise which provides for a full deduction of the underlying Shares from the maximum number issuable under the Plan;

(c)        to change the eligibility for and limitations on participation in the Plan (other than amendments of the Plan to increase any maximum limit of the number of securities that may be issued or issuable which may be specified in the Plan as described in clause (f) in the next paragraph or the reintroduction of participation by non-management directors);

(d)        to change the terms, conditions and mechanics of grant, vesting, exercise and early expiry of options or SARs;

(e)        to change the provisions for termination of options and SARs so long as the change does not permit the Corporation to grant an option or SAR in 2005 or later with an Expiry Date of more than seven years or extend the Expiry Date applicable to an outstanding option or SAR connected therewith;

(f)        to make any addition, deletion or alteration designed to respond to or comply with any applicable law or any tax, accounting, auditing or regulatory or stock exchange rule, provision or requirement or to allow optionholders to receive fair and equitable tax treatment under any applicable tax legislation; and

(g)        to change the transferability of options (including any SARs connected therewith) to permit a transfer or assignment to a spouse or other family member, an entity controlled by the optionee or spouse or family member, an RRSP or RRIF of the optionee, spouse or family member, a trustee, custodian or administrator acting on behalf of, or for the benefit of, the optionee, spouse or family member, any person recognized as a permitted assign in such circumstances in securities or stock exchange regulatory provisions, or for estate planning or estate settlement purposes.

                  Notwithstanding the preceding paragraph, the Board of Directors may not, without approval by the affirmative vote of not less than a majority of the votes cast by the holders of Shares voting in person or by proxy at a meeting of holders of Shares (excluding, to the extent required pursuant to any applicable rules or regulations of any stock exchange on which the Shares are listed, votes of securities held directly or indirectly by insiders benefiting from the amendment), amend this Plan or any option to:
(a)        increase the number of Shares that can be issued under the Plan, including an increase to the fixed maximum number of securities issuable under the Plan, either as fixed number or a fixed percentage of the Corporation's outstanding capital represented by such securities;

(b)        reduce the exercise price or purchase price of an outstanding option (including a cancellation of an outstanding option for the purpose of exchange for reissuance at a lower exercise price to the same person);

(c)        extend the Expiry Date of an option (except with respect to a Blackout Period as described in Section E above) or amend the Plan to permit the grant of an option in 2005 or later with an Expiry Date of more than seven years from the day the option is granted;

(d)        expand the class of eligible recipients of options under the Plan that would permit the introduction or reintroduction of non-employee directors;

(e)        expand the transferability or assignability of options (including any SARs connected therewith), other than an amendment that would permit transfer or assignment of an option (including any SARs connected therewith) to a spouse or other family member, an entity controlled by the option holder or spouse or family member, an RRSP or RRIF of the option holder, spouse or family member, a trustee, custodian or administrator acting on behalf of, or for the benefit of, the option holder, spouse or family member, any person recognized as a permitted assign in such circumstances in securities or stock exchange regulatory provisions, or for estate planning or estate settlement purposes;

(f)        amend the Plan to increase any maximum limit of the number of securities:

(i)        issued to insiders of the Corporation within any one year period, or

(ii)       issuable to insiders of the Corporation at any time; 

which may be specified in the Plan, when combined with all of the Corporation's other security based compensation arrangements, to be in excess of 10% of the Corporation's total issued and outstanding securities, respectively;

(g)        if the Plan has a fixed maximum number of securities issuable, add any provision that allows for the exercise of options without cash consideration, whether the option holder receives the intrinsic value in the form of securities from treasury or the intrinsic value in cash, which does not provide for a full deduction of the underlying Shares from the maximum number issuable under the Plan or, if the Plan does not have a fixed maximum number of securities issuable, add any provision that allows for the exercise of options without cash consideration where a deduction may not be made for the number of Shares underlying the options from the Plan reserve; and

(h)        change the amendment provisions of the Plan;

provided that shareholder approval will not be required for increases or decreases or adjustment to the number of Shares subject to the Plan, deliverable upon the exercise of any option or subject to SARs, or adjustment in the exercise price for shares covered by options and the making of appropriate provisions for the continuance of the options and SARs outstanding under the Plan to prevent their dilution or enlargement in accordance with the section or sections of the Plan which provide for such increase, decrease, adjustments or provisions in respect of certain events, including the subdivision or consolidation of the Shares or reorganization, merger, consolidation or amalgamation of the Corporation, or for the amendment of such section or sections.

                  As used herein "insider" has the meaning given to that term in the Securities Act (British Columbia) and also includes "associates" (within the meaning of that expression as used in the Securities Act (British Columbia)) and affiliates of an insider, but does not include any categories of persons that the Toronto Stock Exchange (the "TSX") or the staff of the TSX in the rules, regulations, policies and staff notices issued or published by the TSX indicate should be excluded from the definition of insider or that the TSX will not consider an insider a listed issuer for the purposes of the TSX's rules, regulations, requirement and policies applicable to security based compensation arrangements, including, without limitation, directors or senior officers of a subsidiary or affiliate of the Corporation unless such director or officer:
(a)        in the ordinary course receives or has access to information as material facts or material changes concerning the Corporation before the material facts or material changes are generally disclosed;

(b)        is a director or senior officer of a "major subsidiary" of the Corporation (where "major subsidiary" has the meaning given to that term in National Instrument 55-101); or

(c)        is an insider of the Corporation in a capacity other than as a director or senior officer of the subsidiary or affiliate.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]